• Home
  • Covid-19
  • Tools
    • Introduction to the Tools
    • Model Government Use Licences
    • Model Uses of Paragraph 7 or “LDC Waiver”
    • Special Compulsory Licences for Export of Medicines
    • Options for Regional Economic Communities
    • Voluntary Licences
  • TRIPS Flexibilities Database
  • Resources
    • Briefs & Briefing Documents
    • Publications
    • Tools
    • Useful Links
    • All Resources
  • Blog
  • About
Search
Medicines Law & Policy Research and resources on intellectual property and health
  • Home
  • Covid-19
  • Tools
    • Introduction to the Tools
    • Model Government Use Licences
    • Model Uses of Paragraph 7 or “LDC Waiver”
    • Special Compulsory Licences for Export of Medicines
    • Options for Regional Economic Communities
    • Voluntary Licences
  • TRIPS Flexibilities Database
  • Resources
    • Briefs & Briefing Documents
    • Publications
    • Tools
    • Useful Links
    • All Resources
  • Blog
  • About

Tag: Sofosbuvir

Price, profit and the Covid-19 health technology pool: The example of...

Christopher Garrison - May 28, 2020

The Power of TRIPS Flexibilities in Medicines Procurement

Ellen 't Hoen - April 9, 2018

Wrapping Up 2017 – some noteworthy medicines law and policy events.

Ellen 't Hoen - December 31, 2017

Medicines Excitement in the Netherlands – New Health Minister announces...

Ellen 't Hoen - November 24, 2017

Gilead’s sofosbuvir patent in India – options for global access to...

Ellen 't Hoen - May 26, 2016

Recent Posts

  • Proposed TRIPS waiver a hollow diplomatic compromise with little practical impact
  • The US NIH will share technology with WHO to fight the pandemic
  • With technology transfer, 120 companies in low- and middle-income countries could manufacture mRNA vaccines
  • Wrapping up 2021 – some noteworthy medicines law and policy events

Posts by Subject

Access to Medicines ARIPO C-TAP Cancer CDCA competition law Compulsory licensing compulsory licensing for export covid-19 Covid-19 Pool Covid-19 vaccine Data exclusivity Delinkage DNDi dolutegravir essential medicines list European Commission European Union evergreening Fair Pricing Gilead Hepatitis C HIV IFPMA LDCs market exclusivity Medicines Patent Pool Medicines Pricing Netherlands Orphan Drugs Patents PrEP R&D remdesivir Sofosbuvir SPC Supplementary Protection Certificates The Netherlands TRIPS flexibilities TRIPS Waiver Truvada vaccines WHO WIPO WTO
Medicines Law & Policy releases analysis, policy recommendations and tools to aid practitioners working on universal access to medicines. We strive to provide information that is as accurate as possible, and we welcome and encourage feedback. For comments or questions contact us at: office@medicineslawandpolicy.net.
  • Home
  • Covid-19
  • Tools
    • Introduction to the Tools
    • Model Government Use Licences
    • Model Uses of Paragraph 7 or “LDC Waiver”
    • Special Compulsory Licences for Export of Medicines
    • Options for Regional Economic Communities
    • Voluntary Licences
  • TRIPS Flexibilities Database
  • Resources
    • Briefs & Briefing Documents
    • Publications
    • Tools
    • Useful Links
    • All Resources
  • Blog
  • About
 This work is licensed under Creative Commons.